Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/IGrRPbKKB2U   The veteran MAO inhibitor phenelzine, branded as Nardil, may help control recurrent prostatic cancer.  Oncologists at USC studied 20 prostatic cancer patients with persistently elevated levels of prostate-specific antigen, PSA, following definitive surgery or radiation therapy for prostatic cancer.   The men were treated with phenelzine 30 mg twice daily for 3 months.  Results showed that 24% had PSA drops of more than 30% and 6% had drops of more than 50%.  The downsides of treatment include dizziness and blood pressure elevation.    Mono-amine oxidase inhibitors block androgen receptor function and prostate cancer growth.  This drug may help fight this second most common cancer in men when other treatment fails.   Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek K. Pinski, David I. Quinn, Olga Castellanos, Patrick Gilmore, Jean C. Shih. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prost